Impact of vitreomacular adhesion on ranibizumab mono- and combination therapy for neovascular age-related macular degeneration

American Journal of Ophthalmology

Volumn 158, Issue 2, 2014, Pages

  Waldstein, Sebastian M ^a   Ritter, Markus ^a   Simader, Christian ^a   Mayr Sponer, Ulrike ^a   Kundi, Michael ^b   Schmidt Erfurth, Ursula ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Medical University of Vienna and Wiener Werkstaette for Suicide Research   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VERTEPORFIN;

AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CENTRAL RETINAL THICKNESS; DRUG EFFICACY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NEOVASCULAR RETINA MACULA AGE RELATED DEGENERATION; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHOTODYNAMIC THERAPY; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; VITREOMACULAR ADHESION; VITREOUS BODY DETACHMENT;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULA LUTEA; MACULAR DEGENERATION; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TIME FACTORS; TISSUE ADHESIONS; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 84905105817     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2014.04.028     Document Type: Article

References (37)

1. L.S. Lim, P. Mitchell, J.M. Seddon, F.G. Holz, and T.Y. Wong Age-related macular degeneration Lancet 379 9827 2012 1728 1738
2. N. Ferrara, L. Damico, N. Shams, H. Lowman, and R. Kim Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 8 2006 859 870
3. P.J. Rosenfeld, D.M. Brown, and J.S. Heier et al. Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1419 1431
4. D.M. Brown, P.K. Kaiser, and M. Michels et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1432 1444
5. A.E. Fung, G.A. Lalwani, and P.J. Rosenfeld et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration Am J Ophthalmol 143 4 2007 566 583
6. D.F. Martin, M.G. Maguire, G.S. Ying, J.E. Grunwald, S.L. Fine, and G.J. Jaffe Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 20 2011 1897 1908
7. D.F. Martin, M.G. Maguire, and S.L. Fine et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 7 2012 1388 1398
8. U. Chakravarthy, S.P. Harding, and C.A. Rogers et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial Ophthalmology 119 7 2012 1399 1411
9. U. Chakravarthy, S.P. Harding, and C.A. Rogers et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial Lancet 382 9900 2013 1258 1267
10. S.Y. Cohen, G. Mimoun, and H. Oubraham et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study Retina 33 3 2013 474 481
11. C. Simader, M. Ritter, and M. Bolz et al. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration Ophthalmology 2014 10.1016/j.ophtha.2013.12.029
12. T.L. Jackson, E. Nicod, and A. Angelis et al. Vitreous attachment in age-related macular degeneration, diabetic macular edema, and retinal vein occlusion: a systematic review and metaanalysis Retina 33 6 2013 1099 1108
13. S.J. Lee, and H.J. Koh Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration Ophthalmology 118 1 2011 101 110
14. G.O. Uney, N. Unlu, and M.A. Acar et al. Role of posterior vitreous detachment on outcome of anti-vascular endothelial growth factor treatment in age-related macular degeneration Retina 34 1 2014 32 37
15. J.S. Duker, P.K. Kaiser, and S. Binder et al. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole Ophthalmology 120 12 2013 2611 2619
16. K.B. Schaal, C.E. Pang, M.C. Pozzoni, and M. Engelbert The premacular bursa's shape revealed in vivo by swept-source optical coherence tomography Ophthalmology 121 5 2014 1020 1028
17. A. Kakehashi, C.L. Schepens, and C.L. Trempe Vitreomacular observations. I. Vitreomacular adhesion and hole in the premacular hyaloid Ophthalmology 101 9 1994 1515 1521
18. U. Geck, N. Pustolla, H. Baraki, A. Atili, N. Feltgen, and H. Hoerauf Posterior vitreous detachment following intravitreal drug injection Graefes Arch Clin Exp Ophthalmol 2013 1 5
19. P. Stalmans, M.S. Benz, and A. Gandorfer et al. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes N Engl J Med 367 7 2012 606 615
20. A.E. Green-Simms, B.M. Fechtel, Z. Agarwal, and S.J. Bakri Visual and anatomical outcomes of anti-vascular endothelial growth factor therapy in exudative age-related macular degeneration and vitreomacular interface disease: vitreomacular adhesion and epiretinal membrane Retina 33 7 2013 1359 1364
21. U. Mayr-Sponer, S.M. Waldstein, and M. Kundi et al. Influence of the vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related macular degeneration Ophthalmology 120 12 2013 2620 2629
22. VIP Study Group Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy Report 2 Am J Ophthalmol 131 5 2001 541 560
23. TAP Study Group Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP Report 2 Arch Ophthalmol 119 2 2001 198 207
24. U. Schmidt-Erfurth, M. Niemeyer, W. Geitzenauer, and S. Michels Time course and morphology of vascular effects associated with photodynamic therapy Ophthalmology 112 12 2005 2061 2069
25. U. Schmidt-Erfurth, U. Schlötzer-Schrehard, C. Cursiefen, S. Michels, A. Beckendorf, and G.O.H. Naumann Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor Invest Ophthalmol Vis Sci 44 10 2003 4473 4480
26. W. Chan, T.-H. Lim, A. Pece, R. Silva, and N. Yoshimura Verteporfin PDT for non-standard indications - a review of current literature Graefes Arch Clin Exp Ophthalmol 248 5 2010 613 626
27. M. Larsen, U. Schmidt-Erfurth, and P. Lanzetta et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results Ophthalmology 119 5 2012 992 1000
28. P.K. Kaiser, D.S. Boyer, A.F. Cruess, J.S. Slakter, S. Pilz, and A. Weisberger Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI Study Ophthalmology 119 5 2012 1001 1010
29. A. Koh, W.K. Lee, and L.-J. Chen et al. EVEREST Study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy Retina 32 8 2012 1453 1464
30. K. Tozer, A.B. Roller, and L.P. Chong et al. Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents Ophthalmology 120 10 2013 2029 2034
31. I. Krebs, W. Brannath, C. Glittenberg, F. Zeiler, J. Sebag, and S. Binder Posterior vitreomacular adhesion: a potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol 144 5 2007 741 746
32. C.D. Robison, I. Krebs, and S. Binder et al. Vitreomacular adhesion in active and end-stage age-related macular degeneration Am J Ophthalmol 148 1 2009 79 82
33. F. Mojana, L. Cheng, and D.U. Bartsch et al. The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results Am J Ophthalmol 146 2 2008 218 227
34. S.J. Lee, C.S. Lee, and H.J. Koh Posterior vitreomacular adhesion and risk of exudative age-related macular degeneration: paired eye study Am J Ophthalmol 147 4 2009 621 626
35. S.M. Waldstein, U. Sponer, C. Simader, S. Sacu, and U. Schmidt-Erfurth Influence of vitreomacular adhesion on the development of exudative age-related macular degeneration: 4-year results of a longitudinal study Retina 32 3 2012 424 433
36. U.M. Schmidt-Erfurth, and S. Michels Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin Ophthalmology 110 7 2003 1306 1314
37. H. Itakura, and S. Kishi Evolution of vitreomacular detachment in healthy subjects JAMA Ophthalmol 131 10 2013 1348 1352